hit counter
Cleveland BioLabs, Inc. (CBLI) Stock News Sentiment & Price - Sentifly
CBLI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cleveland BioLabs, Inc. (CBLI)

USA
Biotechnology
NASDAQ
CBLI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CBLI Latest news
PRNewsWire
Neutral
Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
2021-08-31 07:32

FORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corporate name to "Statera BioPharma, Inc." and update its ticker symbol to "STAB" effective Wednesday, September 1, 2021.

Seeking Alpha
Neutral
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
2021-08-16 11:22

Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript

PRNewsWire
Neutral
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
2021-08-16 10:34

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results conference call may be accessed from the "Investors" section of the Cytocom website at https://www.cytocom.com/investors/.

PRNewsWire
Neutral
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
2021-08-16 07:30

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

PRNewsWire
Neutral
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
2021-08-12 16:05

FORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research.

PRNewsWire
Neutral
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
2021-08-11 07:30

FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021.

PRNewsWire
Neutral
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
2021-08-10 07:30

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m.

PRNewsWire
Neutral
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
2021-08-09 07:30

FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc.  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.

PRNewsWire
Neutral
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
2021-08-05 07:33

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

PRNewsWire
Neutral
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
2021-07-29 07:33

FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.

Loading more news...